Ipsen: A Global Specialty Biopharmaceutical Company
Ipsen S.A. is a prominent, global specialty biopharmaceutical company with its headquarters located in Boulogne-Billancourt, France, and is publicly traded on the Euronext Paris exchange. The company was founded in 1929 and has evolved from a family-owned pharmaceutical business to a focused, global player in specialty care. Ipsen???s strategy is centered on developing and commercializing innovative medicines across three core therapeutic areas: Oncology, Rare Diseases, and Neuroscience. The company operates on a model of targeted research and development (R&D), combined with strategic acquisitions and partnerships, to address significant unmet medical needs.
Continue…Core Business and Therapeutic Areas
Ipsen concentrates its efforts on prescription drugs that offer specialized care, enabling it to maintain a competitive niche within the biopharmaceutical sector. The company invests significantly in R&D to drive advancements in its core areas and is actively involved in the discovery, development, manufacturing, and global commercialization of its products.
1. Oncology
Oncology is the largest therapeutic area for Ipsen, encompassing treatments for various types of solid tumors and hematology. The company has established itself as a significant player in this field, particularly for neuroendocrine tumors and renal cell carcinoma. Its portfolio in this segment is driven by targeted therapies that aim to improve patient outcomes and quality of life.
2. Rare Diseases
Ipsen is committed to developing treatments for rare, debilitating, and often genetic disorders where therapeutic options are limited. This focus area includes conditions such as hormonal, metabolic, and bone diseases. Through its work in Rare Diseases, Ipsen seeks to make a positive impact on the lives of patients and their families dealing with complex health challenges. The company has also supported research in this area through the Fondation Ipsen.
3. Neuroscience
In the Neuroscience area, Ipsen leverages its expertise in neurotoxins for the treatment of various neurological disorders. The focus is on therapies that can alleviate symptoms and improve motor function for patients suffering from conditions like spasticity and cervical dystonia.
Products and Services
Ipsen's commercial offerings are exclusively concentrated in its specialty care segments, following the divestment of its Consumer HealthCare (CHC) division in 2022. The core service provided is the development, manufacture, and distribution of prescription pharmaceutical products globally, with its medicines registered in more than 100 countries and a direct commercial presence in over 30 countries.
The main products Ipsen offers across its therapeutic areas include:
Oncology Products:
- Somatuline? Depot (lanreotide): A somatostatin analog primarily indicated for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and acromegaly.
- Cabometyx? (cabozantinib): A kinase inhibitor used to treat advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
- Onivyde? (irinotecan liposome injection): A liposomal drug indicated, in combination with other agents, for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. It has also received regulatory approvals for use in first-line treatment for mPDAC in combination with the NALIRIFOX regimen.
- Tazverik? (tazemetostat): A first-in-class, chemotherapy-free EZH2 inhibitor for adults with relapsed or refractory follicular lymphoma and for certain patients with epithelioid sarcoma.
- Decapeptyl? (triptorelin): Used for the treatment of hormone-dependent conditions such as prostate cancer and central precocious puberty.
Neuroscience Products:
- Dysport? (abobotulinumtoxinA): A botulinum toxin type A product used for the treatment of various indications, including spasticity in adults and children, and cervical dystonia.
Rare Disease Products:
- Sohonos??? (palovarotene): An orally bioavailable retinoic acid receptor gamma (RAR?) agonist developed to treat patients with fibrodysplasia ossificans progressiva (FOP), a very rare, progressive genetic disorder.
- Iqirvo? (elafibranor): An oral, once-daily peroxisome proliferator-activated receptor alpha/delta (PPAR ?/?) agonist approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) or as monotherapy.
- Bylvay? (odevixibat): Used to treat pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).
R&D and Manufacturing
Ipsen also has a significant global presence through its research and development facilities, with major hubs in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. These centers are responsible for fueling its pipeline with innovative drug candidates across its specialty care focus areas, ensuring a continuous flow of new treatment options through both internal innovation and external deals.
